For patients with very advanced Retinitis Pigmentosa (RP) who have lost nearly all their photoreceptor cells, gene replacement therapy is no longer viable because the target cells (rods and cones) are gone. This critical unmet need is being addressed by optogenetics, a revolutionary, "mutation-agnostic" therapeutic strategy that works regardless of the specific genetic cause of the disease....
The year 2026 marks a transformative period in the treatment of Retinitis Pigmentosa (RP) as the industry shifts its focus toward therapies that work regardless of a patient's specific genetic mutation. For years, the only available gene therapy, Luxturna, was limited to a tiny fraction of patients with the RPE65 mutation. However, 2026 is seeing the clinical maturity of "mutation-agnostic"...
Retinitis pigmentosa gene therapy — the viral vector-mediated delivery of functional copies of mutated genes responsible for inherited photoreceptor degeneration — represents the most transformative development in retinitis pigmentosa treatment, with the Retinitis Pigmentosa Treatment Market reflecting gene therapy as the market-defining treatment innovation.
Luxturna (voretigene...
Accurate and timely diagnosis, anchored by comprehensive genetic testing, is an increasingly crucial element of the Retinitis Pigmentosa (RP) treatment paradigm. Given that the only approved curative treatment (Luxturna) is gene-specific, identifying the causative mutation is the critical first step to determining a patient's eligibility for current and pipeline gene therapies. The use of...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
คลิกดาวน์โหลด
china 
thai
English
French
Spanish
Portuguese
Italiano
Romaian
Portuguese (Brazil)